Rapid advancements in the area of early cancer detection have brought us closer to
achieving the goals of finding cancer early enough to treat or cure it, while avoiding harms of …

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative
review - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

Background Resistance to osimertinib in advanced EGFR-mutated non-small cell lung
cancer (NSCLC) constitutes a significant challenge for clinicians either in terms of molecular …

Importance Liquid biopsy has emerged as a complement to tumor tissue profiling for
advanced non–small cell lung cancer (NSCLC). The optimal way to integrate liquid biopsy …

Biomarker testing is key for non-small cell lung cancer (NSCLC) management and plasma
based next-generation sequencing (NGS) is increasingly characterized as a non-invasive …

The advent of molecular profiling and the generalization of next generation sequencing in
oncology has enabled the identification of patients who could benefit from targeted agents …

Objectives We aimed to evaluate the activity of selinexor, an oral selective inhibitor of
nuclear export, in patients with recurrent or metastatic salivary gland tumors (SGT). Methods …

Simple Summary A liquid biopsy (LB) is now considered to be a valuable diagnostic tool for
advanced and metastatic nonsquamous nonsmall cell lung cancer (NS-NSCLC) patients …

Classic Hodgkin lymphoma (cHL) consists of a heterogeneous group of haematological
disorders that covers undifferentiated B cell neoplasms originating from germinal centre B …

Introduction Tissue and plasma-based NGS have complementary roles in patients with
advanced NSCLC. However, whether there is any added clinical value in combining both …